European Approval For Roche’s Pegasys Personalises Treatment For A Subgroup Of Hepatitis C Patients
Roche also announces start of NCORE study to determine best length of treatment in patients who do not experience a rapid response Roche announced that the European Commission has approved a shortened, 16-week course of treatment with Pegasys (peginterferon alfa-2a (40 KD)) plus Copegus (ribavirin) for certain hepatitis C patients.
More: continued here
Filed under: Liver Disease / Hepatitis on July 25th, 2008